Vigneron Clara, Charpentier Julien, Valade Sandrine, Alexandre Jérôme, Chelabi Samy, Palmieri Lola-Jade, Franck Nathalie, Laurence Valérie, Mira Jean-Paul, Jamme Matthieu, Pène Frédéric
Service de Médecine Intensive-Réanimation, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP). Centre & Université de Paris, Paris, France.
Service de Médecine Intensive-Réanimation, Hôpital Saint-Louis, AP-HP. Nord & Université de Paris, Paris, France.
Ann Intensive Care. 2021 Dec 24;11(1):182. doi: 10.1186/s13613-021-00968-5.
Major therapeutic advances including immunotherapy and targeted therapies have been changing the face of oncology and resulted in improved prognosis as well as in new toxic complications. The aim of this study is to appraise the trends in intensive care unit (ICU) admissions and outcomes of critically ill patients with solid malignancies. We performed a retrospective single-centre study over a 12-year period (2007-2018) including adult patients with solid malignancies requiring unplanned ICU admission. Admission patterns were classified as: (i) specific if directly related to the underlying cancer; (ii) non-specific; (iii) drug-related or procedural adverse events.
1525 patients were analysed. Lung and gastro-intestinal tract accounted for the two main tumour sites. The proportion of patients with metastatic diseases increased from 48.6% in 2007-2008 to 60.2% in 2017-2018 (p = 0.004). Critical conditions were increasingly related to drug- or procedure-related adverse events, from 8.8% of ICU admissions in 2007-2008 to 16% in 2017-2018 (p = 0.01). The crude severity of critical illness at ICU admission did not change over time. The ICU survival rate was 77.4%, without any significant changes over the study period. Among the 1279 patients with complete follow-up, the 1-year survival rate was 33.2%. Independent determinants of ICU mortality were metastatic disease, cancer in progression under treatment, admission for specific complications and the extent of organ failures (invasive and non-invasive ventilation, inotropes/vasopressors, renal replacement therapy and SOFA score). One-year mortality in ICU-survivors was independently associated with lung cancer, metastatic disease, cancer in progression under treatment, admission for specific complications and decision to forgo life-sustaining therapies.
Advances in the management and the prognosis of solid malignancies substantially modified the ICU admission patterns of cancer patients. Despite underlying advanced and often metastatic malignancies, encouraging short-term and long-term outcomes should help changing the dismal perception of critically ill cancer patients.
包括免疫疗法和靶向疗法在内的重大治疗进展正在改变肿瘤学的面貌,不仅改善了预后,还带来了新的毒性并发症。本研究旨在评估重症监护病房(ICU)收治实体恶性肿瘤重症患者的趋势及预后。我们进行了一项为期12年(2007 - 2018年)的回顾性单中心研究,纳入需要非计划入住ICU的成年实体恶性肿瘤患者。入住模式分为:(i)特异性的,即与潜在癌症直接相关;(ii)非特异性的;(iii)药物相关或手术相关不良事件。
共分析了1525例患者。肺癌和胃肠道是两个主要的肿瘤部位。转移性疾病患者的比例从2007 - 2008年的48.6%增至2017 - 2018年的60.2%(p = 0.004)。危急情况越来越多地与药物或手术相关不良事件有关,从2007 - 2008年ICU入院患者的8.8%增至2017 - 2018年的16%(p = 0.01)。ICU入院时危急疾病的粗严重程度随时间未发生变化。ICU生存率为77.4%,在研究期间无显著变化。在1279例有完整随访的患者中,1年生存率为33.2%。ICU死亡的独立决定因素包括转移性疾病、治疗中进展的癌症、因特定并发症入院以及器官衰竭程度(有创和无创通气、血管活性药物使用、肾脏替代治疗和序贯器官衰竭评估(SOFA)评分)。ICU幸存者的1年死亡率独立相关因素包括肺癌、转移性疾病、治疗中进展的癌症、因特定并发症入院以及放弃生命维持治疗的决定。
实体恶性肿瘤管理和预后的进展显著改变了癌症患者的ICU入住模式。尽管存在潜在的晚期且常为转移性恶性肿瘤,但令人鼓舞的短期和长期预后应有助于改变对重症癌症患者的悲观看法。